In short
Fluoroestradiol F-18 is an innovative radiopharmaceutical being studied in clinical trials for its potential to improve treatment decisions in patients with estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer. These trials aim to evaluate how Fluoroestradiol F-18 PET/CT imaging can guide therapy choices and impact patient outcomes after progression on initial hormone therapies.
At a glance
- Drug Name
- Fluoroestradiol F-18 (EstroTep)
- Type of Drug
- Radiopharmaceutical for PET/CT imaging
- Target Patient Population
- ER-positive, HER2-negative metastatic breast cancer patients who progressed on first-line therapy with CDK4/6 inhibitor and aromatase inhibitor
- Primary Objectives
- Assess the impact of Fluoroestradiol F-18 PET/CT on treatment decisions and evaluate its efficacy in guiding second-line therapy choices
- Key Secondary Objectives
- Evaluate progression-free survival, overall survival, objective response rate, and clinical benefit rate
- Administration
- Intravenous injection, up to 400 MBq
- Trial Designs
- Randomized, multicentric, open-label, phase III and IV studies
- Potential Benefits
- Improved treatment decision-making, potentially leading to better patient outcomes
What is FLUOROESTRADIOL F-18?
FLUOROESTRADIOL F-18, also known as 18F-FES or 16α-18F-fluoro-17β-oestradiol, is a diagnostic tool used in medical imaging. It's a radioactive substance that helps doctors see specific areas in your body using a special type of scan called PET/CT (Positron Emission Tomography/Computed Tomography).
How is it used?
FLUOROESTRADIOL F-18 is primarily used to help diagnose and manage a specific type of breast cancer. It works by attaching to estrogen receptors in the body, which are often found in high numbers in certain breast cancers. When used with a PET/CT scan, it can show doctors where these receptors are located, helping them to:
- Determine if the cancer has spread to other parts of the body
- Guide treatment decisions
- Monitor how well the treatment is working
Who can benefit from FLUOROESTRADIOL F-18?
This diagnostic tool is specifically designed for patients with:
- Metastatic breast cancer: Cancer that has spread from the breast to other parts of the body
- ER-positive breast cancer: Cancer cells that have estrogen receptors on their surface
- HER2-negative breast cancer: Cancer cells that don't have high levels of a protein called HER2
It's particularly useful for patients who have already undergone initial treatment and are experiencing a relapse or progression of their disease.
Current Clinical Trials
FLUOROESTRADIOL F-18 is currently being studied in clinical trials to further understand its benefits. Two notable studies are:
- The ECLECTIC Trial: This study is looking at how FLUOROESTRADIOL F-18 PET/CT scans, along with other tests, can help guide treatment decisions for patients whose cancer has progressed after initial therapy.
- The ESTROTIMP Trial: This trial is investigating how FLUOROESTRADIOL F-18 PET/CT scans might impact treatment management for patients with metastatic breast cancer who have relapsed after their first line of treatment.
How is FLUOROESTRADIOL F-18 administered?
FLUOROESTRADIOL F-18 is given as an intravenous injection (into a vein) before a PET/CT scan. The dose is typically measured in units called megabecquerels (MBq), with a maximum dose of about 400 MBq. The exact dose may vary based on your body weight, usually around 4 MBq per kilogram of body weight.
Safety Considerations
While FLUOROESTRADIOL F-18 is generally considered safe, there are some important points to consider:
- It should not be used in patients with known allergies to any of its components.
- It's not recommended for use in pregnant or breastfeeding women.
- Patients with severe liver or kidney problems may need special consideration.
- As with any medical procedure involving radiation, the benefits should outweigh the potential risks.
Always discuss any concerns or questions with your healthcare provider. They can provide more detailed information based on your specific medical history and condition.